Immunomodulatory effect of a proprietary polyherbal formulation on healthy participants: A single- blind, randomized, placebo- controlled, exploratory clinical study.

Q2 Medicine Perspectives in Clinical Research Pub Date : 2023-07-01 Epub Date: 2023-05-22 DOI:10.4103/picr.picr_100_22
Suresh Khadke, Poonam Gupte, Akanksha Mourya, Amit Yadav, Sarika Mane, Asavari Joshi, Madhavi Mahajan, Manisha Mishra, Supriya Bhalerao
{"title":"Immunomodulatory effect of a proprietary polyherbal formulation on healthy participants: A single- blind, randomized, placebo- controlled, exploratory clinical study.","authors":"Suresh Khadke,&nbsp;Poonam Gupte,&nbsp;Akanksha Mourya,&nbsp;Amit Yadav,&nbsp;Sarika Mane,&nbsp;Asavari Joshi,&nbsp;Madhavi Mahajan,&nbsp;Manisha Mishra,&nbsp;Supriya Bhalerao","doi":"10.4103/picr.picr_100_22","DOIUrl":null,"url":null,"abstract":"<p><strong>Context: </strong>Clinical study for immunity.</p><p><strong>Aims: </strong>The present study aimed to assess the effect of proprietary polyherbal formulation (PPHF), labelled as Kofol immunity tablets (KIT) on innate and adaptive immune responses in healthy individuals, on the backdrop of COVID-19 pandemic.</p><p><strong>Settings and design: </strong>Single-blind, randomized, placebo-controlled, exploratory study in institutional setting.</p><p><strong>Materials and methods: </strong>Post Ethics Committee permission, screened healthy individuals of either sex aged 18-35 years were randomized to PPHF/Placebo for 2 months. Major assessment variables included peak expiratory flow rate (PEFR), questionnaire-based immune status, perceived stress, and quality of life (QOL) with immune-specific cell counts (CD4+, CD8+), cytokines (interferon gamma [IFN-γ], tumor necrosis factor-alpha [TNF-α], interleukin 10 [IL-10]), and oxidative stress in red blood cells (RBCs) (malondialdehyde (MDA), glutathione peroxidase [GPx]), done at day 60.</p><p><strong>Statistical analysis used: </strong>Mean ± standard deviation and paired/unpaired <i>t-</i>test for parametric data analysis while median (range) and Wilcoxon Rank sum test/Mann-Whitney test for nonparametric data analysis, were done. Categorical data was analyzed using Chi-square test. GraphPad InStat software, version 9 was used with <i>p</i> < 0.05, as the level of statistical significance.</p><p><strong>Results: </strong>Of 52 recruited, 28 individuals completed the study. PPHF significantly increased PEFR, improved immune status along with QOL compared to baseline. It also decreased perceived stress from moderate and severe grade to mild. Serum IFN-γ levels remained almost constant post-PPHF treatment. PPHF significantly decreased MDA and increased GPx in RBCs. Significant decrease and increase in TNF-α and IL-10, respectively, were seen in PPHF group. The safety parameters post-PPHF treatment remained within normal reference ranges.</p><p><strong>Conclusions: </strong>PPHF is an efficacious and safe formulation with immunomodulatory potential.</p>","PeriodicalId":20015,"journal":{"name":"Perspectives in Clinical Research","volume":"14 3","pages":"130-138"},"PeriodicalIF":0.0000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9e/8d/PCR-14-130.PMC10405535.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Perspectives in Clinical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/picr.picr_100_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/5/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Context: Clinical study for immunity.

Aims: The present study aimed to assess the effect of proprietary polyherbal formulation (PPHF), labelled as Kofol immunity tablets (KIT) on innate and adaptive immune responses in healthy individuals, on the backdrop of COVID-19 pandemic.

Settings and design: Single-blind, randomized, placebo-controlled, exploratory study in institutional setting.

Materials and methods: Post Ethics Committee permission, screened healthy individuals of either sex aged 18-35 years were randomized to PPHF/Placebo for 2 months. Major assessment variables included peak expiratory flow rate (PEFR), questionnaire-based immune status, perceived stress, and quality of life (QOL) with immune-specific cell counts (CD4+, CD8+), cytokines (interferon gamma [IFN-γ], tumor necrosis factor-alpha [TNF-α], interleukin 10 [IL-10]), and oxidative stress in red blood cells (RBCs) (malondialdehyde (MDA), glutathione peroxidase [GPx]), done at day 60.

Statistical analysis used: Mean ± standard deviation and paired/unpaired t-test for parametric data analysis while median (range) and Wilcoxon Rank sum test/Mann-Whitney test for nonparametric data analysis, were done. Categorical data was analyzed using Chi-square test. GraphPad InStat software, version 9 was used with p < 0.05, as the level of statistical significance.

Results: Of 52 recruited, 28 individuals completed the study. PPHF significantly increased PEFR, improved immune status along with QOL compared to baseline. It also decreased perceived stress from moderate and severe grade to mild. Serum IFN-γ levels remained almost constant post-PPHF treatment. PPHF significantly decreased MDA and increased GPx in RBCs. Significant decrease and increase in TNF-α and IL-10, respectively, were seen in PPHF group. The safety parameters post-PPHF treatment remained within normal reference ranges.

Conclusions: PPHF is an efficacious and safe formulation with immunomodulatory potential.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
专利多羟基制剂对健康参与者的免疫调节作用:一项单盲、随机、安慰剂对照、探索性临床研究。
背景:免疫的临床研究。目的:本研究旨在评估在新冠肺炎大流行的背景下,标记为Kofol免疫片(KIT)的专有多羟基制剂(PPHF)对健康个体先天和适应性免疫反应的影响。设置和设计:在机构环境中进行单盲、随机、安慰剂对照、探索性研究。材料和方法:经伦理委员会批准,筛选出的18-35岁的健康个体随机接受PPHF/安慰剂治疗2个月。主要评估变量包括呼气峰流速(PEFR)、基于问卷的免疫状态、感知压力和生活质量(QOL),包括免疫特异性细胞计数(CD4+、CD8+)、细胞因子(干扰素γ[INF-γ]、肿瘤坏死因子α[TNF-α]、白细胞介素10[IL-10])和红细胞氧化应激(RBCs)(丙二醛(MDA)、谷胱甘肽过氧化物酶[GPx]),在第60天进行。使用的统计分析:参数数据分析采用平均值±标准差和配对/非配对t检验,非参数数据分析则采用中位数(范围)和Wilcoxon秩和检验/Mann Whitney检验。分类数据采用卡方检验进行分析。使用GraphPad InStat软件,版本9,p<0.05,作为统计学显著性水平。结果:在52名被招募者中,28人完成了研究。与基线相比,PPHF显著增加了PEFR,改善了免疫状态和生活质量。它还将感知压力从中度和重度降低到轻度。PPHF治疗后,血清IFN-γ水平几乎保持不变。PPHF显著降低RBCs中MDA含量,增加GPx。PPHF组TNF-α和IL-10分别显著降低和升高。PPHF治疗后的安全性参数保持在正常参考范围内。结论:PPHF是一种具有免疫调节潜力的安全有效的制剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Perspectives in Clinical Research
Perspectives in Clinical Research Medicine-Medicine (all)
CiteScore
2.90
自引率
0.00%
发文量
41
审稿时长
36 weeks
期刊介绍: This peer review quarterly journal is positioned to build a learning clinical research community in India. This scientific journal will have a broad coverage of topics across clinical research disciplines including clinical research methodology, research ethics, clinical data management, training, data management, biostatistics, regulatory and will include original articles, reviews, news and views, perspectives, and other interesting sections. PICR will offer all clinical research stakeholders in India – academicians, ethics committees, regulators, and industry professionals -a forum for exchange of ideas, information and opinions.
期刊最新文献
Evaluation of student-led “Association for Support and Propagation of Innovation, Research, and Education” (A.S.P.I.R.E) in empowering undergraduate medical students in research: A 2-year longitudinal study Pleiotropic effect of teneligliptin versus glimepiride add-on therapy on hs-CRP and cardiorenal parameters in Indian type 2 diabetes patients: An open-labeled randomized controlled trial Efficacy and safety of quick penetrating solution heparin, quick penetrating solution diclofenac, and heparin gel in the prevention of infusion-associated superficial thrombophlebitis: A randomized controlled trial Bio-entrepreneurs’ bugbear: Regulatory rigmarole Experience of participating in community-based clinical trials from rural Maharashtra: Analysis of over 4000 participant feedback forms
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1